Lupin, APL Apollo Tubes among 7 small & midcap stocks that can surge up to 48%

Axis Securities has set a target price of Rs 2,500 on Lupin, showing an upside potential of around 23% from current market prices.

"New launches in the U.S. market, such as Darunavir and Spiriva, have gained market shares of up to 30% and 25%, respectively. The recent approval for gMegabran has the potential to contribute $50 Mn in annual incremental sales. Additionally, approvals for Tolvaptan (market size $287 Mn) and Xyway (market size $958 Mn with 180-day exclusivity) could drive growth in the second half. The company has a robust product pipeline, which includes Cynocobalamin, Diazepam Gel, Varenicline, Bromfenac, Glucagen, and Risperidone, among others," it said.

Axis Securities has set a target price of Rs 1,315 on Max Healthcare Institute, indicating an upside potential of nearly 17% from the current market prices.

"Max Healthcare’s revenue mix remains well balanced, with sustained growth in both institutional and international patient segments. The recent rise in institutional business share is expected to stabilise as higher-value payer segments expand. While new hospital ramp-ups may have a short-term margin impact, this should ease as these facilities scale operations. Profitability in Lucknow and Nagpur is expected to improve further, driven by higher occupancy rates and the introduction of new clinical programs," Axis Securities said.

Axis Securities has set a target price of Rs 2,950 on Colgate-Palmolive, an upside potential of around 16% from the current market prices.

"We appreciate the company’s overall long-term strategy, which focuses on driving top-line growth through initiatives such as: 1) Launching science-based premium products to enhance overall realisations, 2) Developing the category by increasing awareness through marketing initiatives, 3) Increasing the frequency of consumption and penetration in rural markets, and 4) Expanding the personal care portfolio to mitigate risks associated with the slow growing oral care category, moreover demand environment likely to improve in coming quarters and recent stock price correction provide better margin of safety," it said.

The brokerage firm Axis Securities has set a target price of Rs 2,180 on Dalmia Bharat, implying an upside potential of 14% from the current market prices.

"We remain positive on the company's growth prospects and expect it to deliver a Volume/Revenue/EBITDA/PAT CAGR of 8%/6%/11%/17% over FY24-FY27E. Capacity expansion, market share gains, and operational efficiencies will drive this growth. Additionally, with the growing pace of consolidation and capacity expansion by top players, their overall market share is set to increase further to 65%-70% by FY27-28. This trend will positively influence cement pricing, economies of scale, and supply chain efficiency. The company, being among the top 5 players in the country, is well positioned to benefit from this consolidation in the medium to long term," it said.

The brokerage firm Axis Securities maintained a 'Buy' rating on Prestige Estates Projects with a target price of Rs 1,820, showing an upside potential of 42% from the current market prices.

"Despite the absence of major launches this quarter, the company recorded sales of Rs 3,013 Cr (Rs 2,947 Cr attributable to PEPL), showcasing its ability to generate sales from ongoing inventory. Management remains confident in the demand for its projects and expects ~30% sales on launch for upcoming developments. This should support its booking guidance and reinforce a strong pipeline for future project acquisitions," it said.

Axis Securities has set a target price of Rs 1,800 on APL Apollo Tubes, showing an upside potential of around 9% from the current market prices.

"The company’s vision is to expand its capacity to 10 MTPA by FY30, providing a long-term growth tailwind. The current capacity is 4.3MT, which will increase to 5MT by FY26. The residual capex of Rs 500 Cr will bring the total capacity to 5.5 MTPA. We value the company using a Mar’26 EPS (roll forward from Dec’26 EPS estimate), based on a 1-year forward P/E target of 33x, to arrive at our target price of Rs 1,800/share," it said.

Axis Securities has set a target price of Rs 1,350 on Kalpataru Projects International, showing an upside potential of around 48% from the current market prices.

"The company is well-positioned to benefit from a robust order book, favourable sectoral tailwinds in both domestic and international T&D and B&F segments, improved performance of its international subsidiaries, supportive government initiatives, and expected margin improvements. It is projected to deliver a CAGR of 16%, 19%, and 31% over FY24-27E," said the brokerage firm.


(Disclaimer: Recommendations, suggestions, views and opinions given by the experts are their own. These do not represent the views of The Economic Times)